More aggressive antithrombotic strategies might be specifically indicated in patients with diabetes and cardiovascular diseases, including the use of the newer, more potent P2Y12 inhibitors in patients with ACS, DAPT prolongation beyond 1 year in patients with MI, and short-term DAPT in selected patients with acute ischaemic stroke. This evidence concerns the gene P2RY12 and diabetes mellitus.